---
title: "InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292618454.md"
description: "A recent study published in the journal STTT found that orelabrutinib leads to a significant extension in progression-free survival (PFS) and decreases the likelihood of disease progression or mortality by 68%."
datetime: "2026-07-14T11:25:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292618454.md)
  - [en](https://longbridge.com/en/news/292618454.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292618454.md)
generator: "portal-rs"
---

# InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL

A recent study published in the journal STTT found that orelabrutinib leads to a significant extension in progression-free survival (PFS) and decreases the likelihood of disease progression or mortality by 68%.

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)

## Related News & Research

- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [InnoCare’s Oral Psoriasis Drug ICP‑488 Hits Phase III Target, Paving Path to Regulatory Filing](https://longbridge.com/en/news/293910253.md)
- [Oryzon Genomics wins US notice of allowance for iadademstat-gilteritinib AML patent application](https://longbridge.com/en/news/297475261.md)
- [The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership](https://longbridge.com/en/news/298111249.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**